Sinopharm Group Statistics
Total Valuation
Sinopharm Group has a market cap or net worth of HKD 58.29 billion. The enterprise value is 146.41 billion.
Market Cap | 58.29B |
Enterprise Value | 146.41B |
Important Dates
The next estimated earnings date is Thursday, August 28, 2025.
Earnings Date | Aug 28, 2025 |
Ex-Dividend Date | Jun 16, 2025 |
Share Statistics
Sinopharm Group has 3.12 billion shares outstanding. The number of shares has increased by 0.35% in one year.
Current Share Class | 1.34B |
Shares Outstanding | 3.12B |
Shares Change (YoY) | +0.35% |
Shares Change (QoQ) | -0.66% |
Owned by Insiders (%) | n/a |
Owned by Institutions (%) | 29.28% |
Float | 1.34B |
Valuation Ratios
The trailing PE ratio is 7.68 and the forward PE ratio is 7.11. Sinopharm Group's PEG ratio is 1.40.
PE Ratio | 7.68 |
Forward PE | 7.11 |
PS Ratio | 0.09 |
PB Ratio | 0.42 |
P/TBV Ratio | 0.77 |
P/FCF Ratio | 2.32 |
P/OCF Ratio | 2.20 |
PEG Ratio | 1.40 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 5.85, with an EV/FCF ratio of 5.83.
EV / Earnings | 19.27 |
EV / Sales | 0.24 |
EV / EBITDA | 5.85 |
EV / EBIT | 7.26 |
EV / FCF | 5.83 |
Financial Position
The company has a current ratio of 1.34, with a Debt / Equity ratio of 0.61.
Current Ratio | 1.34 |
Quick Ratio | 1.07 |
Debt / Equity | 0.61 |
Debt / EBITDA | 3.56 |
Debt / FCF | 3.37 |
Interest Coverage | 6.65 |
Financial Efficiency
Return on equity (ROE) is 8.24% and return on invested capital (ROIC) is 5.47%.
Return on Equity (ROE) | 8.24% |
Return on Assets (ROA) | n/a |
Return on Invested Capital (ROIC) | 5.47% |
Return on Capital Employed (ROCE) | 12.48% |
Revenue Per Employee | 5.74M |
Profits Per Employee | 70,210 |
Employee Count | 108,217 |
Asset Turnover | n/a |
Inventory Turnover | n/a |
Taxes
Income Tax | n/a |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -13.32% in the last 52 weeks. The beta is 0.59, so Sinopharm Group's price volatility has been lower than the market average.
Beta (5Y) | 0.59 |
52-Week Price Change | -13.32% |
50-Day Moving Average | 18.27 |
200-Day Moving Average | 19.48 |
Relative Strength Index (RSI) | 52.13 |
Average Volume (20 Days) | 7,179,656 |
Short Selling Information
Short Interest | n/a |
Short Previous Month | n/a |
Short % of Shares Out | n/a |
Short % of Float | n/a |
Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Sinopharm Group had revenue of HKD 620.68 billion and earned 7.60 billion in profits. Earnings per share was 2.43.
Revenue | 620.68B |
Gross Profit | 46.71B |
Operating Income | 18.87B |
Pretax Income | 14.82B |
Net Income | 7.60B |
EBITDA | 21.19B |
EBIT | 18.87B |
Earnings Per Share (EPS) | 2.43 |
Balance Sheet
The company has 48.63 billion in cash and 84.58 billion in debt, giving a net cash position of -35.95 billion or -11.52 per share.
Cash & Cash Equivalents | 48.63B |
Total Debt | 84.58B |
Net Cash | -35.95B |
Net Cash Per Share | -11.52 |
Equity (Book Value) | 138.48B |
Book Value Per Share | 27.66 |
Working Capital | 101.12B |
Cash Flow
In the last 12 months, operating cash flow was 26.54 billion and capital expenditures -1.41 billion, giving a free cash flow of 25.12 billion.
Operating Cash Flow | 26.54B |
Capital Expenditures | -1.41B |
Free Cash Flow | 25.12B |
FCF Per Share | 8.05 |
Margins
Gross margin is 7.53%, with operating and profit margins of 3.04% and 1.22%.
Gross Margin | 7.53% |
Operating Margin | 3.04% |
Pretax Margin | 2.39% |
Profit Margin | 1.22% |
EBITDA Margin | 3.41% |
EBIT Margin | 3.04% |
FCF Margin | 4.05% |
Dividends & Yields
This stock pays an annual dividend of 0.74, which amounts to a dividend yield of 3.98%.
Dividend Per Share | 0.74 |
Dividend Yield | 3.98% |
Dividend Growth (YoY) | 6.22% |
Years of Dividend Growth | 4 |
Payout Ratio | 29.23% |
Buyback Yield | -0.35% |
Shareholder Yield | 3.63% |
Earnings Yield | 13.03% |
FCF Yield | 43.10% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
Lynch Fair Value | |
Lynch Upside | |
Graham Number | |
Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
Last Split Date | n/a |
Split Type | n/a |
Split Ratio | n/a |
Scores
Sinopharm Group has an Altman Z-Score of 2.12. A Z-score under 3 suggests an increased risk of bankruptcy.
Altman Z-Score | 2.12 |
Piotroski F-Score | n/a |